Investors Research Corp Raises Position in IQVIA Holdings Inc. $IQV

Key Points

• Investors Research Corp significantly increased its stake in IQVIA Holdings Inc. by 19,772.7% during the 2nd quarter, owning 2,186 shares valued at $344,000.
• Wall Street analysts have a consensus rating of "Moderate Buy" for IQVIA, with an average target price of $229.64, reflecting positive growth expectations.
• Insiders have been active in selling shares, with Keriann Cherofsky and Eric Sherbet both offloading portions of their holdings in transactions on July 23rd.

Investors Research Corp grew its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 19,772.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,186 shares of the medical research company's stock after purchasing an additional 2,175 shares during the period. Investors Research Corp's holdings in IQVIA were worth $344,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Brighton Jones LLC boosted its stake in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after buying an additional 2,537 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of IQVIA by 6.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,001 shares of the medical research company's stock worth $9,826,000 after purchasing an additional 3,236 shares during the period. NorthRock Partners LLC bought a new position in IQVIA during the 4th quarter valued at about $397,000. Nomura Holdings Inc. purchased a new stake in IQVIA in the 4th quarter worth about $1,117,000. Finally, Quantinno Capital Management LP lifted its stake in IQVIA by 43.5% in the fourth quarter. Quantinno Capital Management LP now owns 25,909 shares of the medical research company's stock worth $5,092,000 after purchasing an additional 7,850 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on IQV shares. Redburn Partners set a $214.00 price target on IQVIA in a report on Wednesday, September 3rd. Truist Financial upped their price objective on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Barclays increased their target price on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. Evercore ISI upped their price target on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. Finally, William Blair reiterated an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Eighteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $229.64.

Insider Buying and Selling at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Price Performance

Shares of IQV opened at $187.34 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The company has a 50 day moving average price of $182.40 and a 200-day moving average price of $167.26. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $248.03. The stock has a market capitalization of $31.85 billion, a PE ratio of 27.11, a PEG ratio of 2.09 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. IQVIA's revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.